NASDAQ OMX

LeoVegas publishes prospectus and new financial information in connection with application of admission to trading on Nasdaq Stockholm

Dela

LeoVegas AB (publ) (" LeoVegas ") has to Nasdaq Stockholm AB applied for admission to trading of LeoVegas' shares on the regulated market Nasdaq Stockholm. The Board of Directors of LeoVegas have in connection with the listing on Nasdaq Stockholm prepared a prospectus that today has been approved and registered by the Swedish Financial Supervisory Authority. The prospectus contains, due to regulatory requirements, new financial information as of 31 October 2017 attributable to LeoVegas' capital structure that has not previously been published. LeoVegas expects a formal approval from Nasdaq Stockholm at the latest by 31 January 2018.

The prospectus
The prospectus has been prepared in connection with the application of change in listing from Nasdaq First North Premier to Nasdaq Stockholm. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and published on www.leovegasgroup.com. The prospectus will also within a few days be available on the Swedish Financial Supervisory Authority's web page, www.fi.se.

New financial information
The prospectus includes updated information as of 31 October 2017 attributable to LeoVegas' capital structure. This is due to regulatory requirements which implies that financial information attributable to the capital structure may not be older than 90 days upon the date of the prospectus. This information has previously not been published and the table presented below reproduces this information. The tables only include interest-bearing debts. In essence, the financial figures below reflect what was published in LeoVegas' interim-report for the period 1 January - 30 September 2017.

The tables of equity and liabilities as well as net indebtedness can be found on page 64 of the prospectus.

KEUR 31 Oct 2017 Proforma [1]
Current debt    
Guaranteed - -
Secured - -
Unguaranteed/Unsecured - -
Total Current debt - -
     
KEUR    
Non-Current debt    
Current debt - -
Guaranteed - -
Secured - 75 000
Total Non-Current debt - 75 000
     
Shareholder's equity    
Share capital 1 196   1 196 
Legal Reserve 36 588    36 588 
Other Reserves 19 610    19 610 
Total Shareholders' equity   57 394    57 394 

KEUR 31 Oct 17 Proforma [2]
(A) Cash 63 566  34 580
(B) Cash equivalent -
(C) Trading securities -5 399  -7 699
(D) Liquidity (A)+(B)+(C) 58 167  26 881
     
(E) Current Financial Receivable  - -
     
(F) Current Bank debt  - -
(G) Current portion of non current debt - -
(H) Other current financial debt - -
(I) Current Financial Debt (F)+(G)+(H) - -
     
(J) Net Current Financial Indebtedness (I)-(E)-(D) -58 167  -26 881 
     
(K) Non current Bank Loans - -75 000
(L) Bonds Issued  -
(M) Other non current loans  -
     
(N) Non current Financial Indebtedness (K)+(L)+(M) - -75 000
     
(O) Net Financial Indebtedness (J)+(N) -58 167  -101 881 

The prospectus also includes consolidated pro forma financial statements for LeoVegas regarding the acquisition of Royal Panda and Rocket X including a consolidated pro forma income statement for the period January 2017 - September 2017 and a consolidated pro forma balance sheet as of 30 September, 2017.

Trading on Nasdaq Stockholm
LeoVegas expects a formal approval from Nasdaq Stockholm at the latest AB on by 31 January 2018. Provided that an approval is obtained, the last day of trading on First North Premier is expected to be on 2 February 2018, and the first day for trading on Nasdaq Stockholm is planned to commence on 5 February 2018. LeoVegas' shares will be traded under the same ticker (LEO) and ISIN code (SE0008091904). LeoVegas shareholders do not need to take any action in connection with the change in listing.

Adviser
Baker McKenzie is acting as legal adviser to LeoVegas in connection with the change in listing to Nasdaq Stockholm.

For further information, please contact:

Gustaf Hagman, Group CEO co-founder: +46 70 880 55 22, gustaf.hagman@leovegas.com
Philip Doftvik, Head of Investor Relations: +46 73 512 07 20, philip.doftvik@leovegas.com
Visitors address: Luntmakargatan 18, Stockholm
Corporate identity number: 556830-4033

About the LeoVegas mobile gaming group
LeoVegas' passion is "Leading the way into the mobile future". LeoVegas is Sweden's premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. In 2017 the company passed the threshold for being classified as a unicorn, i.e., a start-up valued at more than USD 1 billion. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sport gaming, and operates two global and scalable brands - LeoVegas and Royal Panda. The company's shares are listed on Nasdaq First North Premier, and Avanza Bank AB is the company's Certified Adviser. For more about LeoVegas, visit  www.leovegasgroup.com .



[1] This information is presented as a result of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.  

[2] This information is presented due to of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Hoylu AB: UNITED STATES ARMY SELECTS HOYLU FOR DIGITAL COLLABORATION SOLUTIONS26.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 26, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Army has selected Hoylu Software and the large format HoyluWall system as a digital workspace tool for workspace collaboration, process planning and ideation. Hoylu software will be used to modify, save, print and communicate between teams at remote locations and allow for collaborative analysis. The order will be delivered in Q3 2018 and represents a deal value of SEK 528,000 in product and software revenue and presents ongoing opportunities to expand within the government sector. This system will be installed at the Picatinny Arsenal in New Jersey, the US Army's primary R&D arm for armament and munitions systems. Picatinny Arsenal is the Joint Center of Excellence for Guns and Ammunition, providing products and services to all branches of the U.S. military. Picatinny Arsenal has partnerships with a variety of universities and industry partners, involving them i

Hoylu AB: USA:s armé väljer Hoylu för digitala samarbetslösningar26.9.2018 08:30Pressmeddelande

Malmö, Sverige, 26:e september 2018 - Hoylu, ett ledande företag inom digitala samarbetslösningar tillkännagav idag att USA:s armé har valt Hoylus mjukvara och storformats Hoylu Wall-system som verktyg för digitalt samarbete, delade arbetsytor, processplanering och idégenerering. Hoylus mjukvara kommer användas till att modifiera, spara, skriva ut och stödja samarbete mellan team på olika platser samt möjliggöra kollaborativ analys. Ordern kommer levereras under tredje kvartalet 2018 och har ett sammanlagt värde på SEK 528 000 för hård- och mjukvara. Ordern visar på ökande möjligheter att växa inom statlig och offentlig verksamhet. Systemet kommer installeras på Picatinny Arsenal i New Jersey, USA:s armés primära R&D-enhet för vapen- och ammunitionssystem. Picatinny Arsenal är ett s.k. "Joint Center of Excellence" för vapen och ammunition och de tillhandahåller produkter och tjänster åt alla grenar av USA:s armé. Picatinny Arsenal har också samarbeten med en mängd olika universitet och

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum